Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2615-L01-P.
Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses. 

Hardware/Software Requirements
The webinar is accessed through Zoom. An internet connection and the system requirements are needed to access the webinar.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Educational Objectives

Upon completion of this program, participants will be able to:

• Properly monitor patients receiving immune effector cell therapies for treatment-related adverse events and identify those at high risk
• Identify common and uncommon toxicities that may occur with immune effector cell therapies
• Determine appropriate management techniques for common adverse events resulting from immune effector cell therapies

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer

This webinar is supported, in part, by independent medical education grants from
Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.